FDA Transparency Initiative: Opening FDA's 'Black Box'


Transparency promotes accountability, enhances the work of the agency, and increases its credibility with the public. This article by FDA's Special Assistant to the Principal Deputy Commissioner, Afia K. Asamoah, and published by FDLI outlines opening the proverbial 'black box' to help FDA more effectively implement its mission to promote and protect the public health.

Author: Afia K. Asamoah, published by FDLI

Find more white papers on cGMPs

View all white papers»